MARKET

ADVM

ADVM

Adverum
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.67
+0.11
+0.95%
After Hours: 11.67 0 0.00% 16:00 10/20 EDT
OPEN
11.66
PREV CLOSE
11.56
HIGH
11.94
LOW
11.53
VOLUME
544.48K
TURNOVER
--
52 WEEK HIGH
26.98
52 WEEK LOW
6.58
MARKET CAP
1.11B
P/E (TTM)
-9.6057
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual
GlobeNewswire · 14h ago
Adverum Biotechnologies To Present New Data From OPTIC Phase 1 Trial Of ADVM-022 Intravitreal Gene Therapy For Wet AMD At AAO 2020 Virtual
Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual -- Dr. Carl Regillo to present OPTIC data at
Benzinga · 15h ago
Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
Zacks · 10/09 13:56
Gene Therapy Stocks - A Buying Opportunity
Some gene therapy stocks including ORTX, QURE and RGNX are trading considerably lower than in January of 2020.ORTX, QURE and RGNX have all had issues unique to their businesses which may explain the depressed share prices.Recently, the FDA has taken a tougher stance on gene therapy in diseases where patients have viable treatment options which may have caused further declines in share price.ORTX shares appears materially undervalued, QURE offers a high degree of risk and a very substantial upside and RGNX can potentially recover if they produce compelling clinical data.
Seekingalpha · 10/06 17:48
Adverum Biotechnologies, Inc. (ADVM) Is Stalling With Hedge Funds
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index
Insider Monkey · 09/29 22:23
Assessing Adverum
Today, we take an in-depth look at Adverum Biotechnologies which has dropped by more than half from highs earlier this year.The company has multiple 'shots on goal' on upcoming potential catalysts. The firm also recently addressed all foreseeable funding needs.A full investment analysis is presented in the paragraphs below.
Seekingalpha · 09/29 17:45
Adverum Biotechnologies Announces Appointment of Christopher J. Morrison, Ph.D. as Vice President, Process Science
GlobeNewswire · 09/15 13:00
Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Cantor Virtual Global Healthcare Conference on Tuesday
GlobeNewswire · 09/10 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADVM. Analyze the recent business situations of Adverum through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADVM stock price target is 27.38 with a high estimate of 36.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 189
Institutional Holdings: 91.51M
% Owned: 96.18%
Shares Outstanding: 95.14M
TypeInstitutionsShares
Increased
59
6.82M
New
43
885.83K
Decreased
38
6.80M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.98%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Independent Director
Patrick Machado
Chairman/Independent Director
C. Patrick Machado
President
Leone Patterson
Chief Executive Officer/Director
Laurent Fischer
Chief Financial Officer
Thomas Leung
Chief Technology Officer
Angela Thedinga
Vice President
Heikki Jouttijarvi
Vice President
Thomas Kochy
Vice President
Christopher Morrison
Other
Aaron Osborne
Other
Peter Soparkar
Director
Mehdi Gasmi
Independent Director
Eric Carter
Independent Director
Rekha Hemrajani
Independent Director
Mark Lupher
Independent Director
James Scopa
Independent Director
Richard Spivey
Independent Director
Scott Whitcup
Independent Director
Thomas Woiwode
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Adverum Biotechnologies Inc stock information, including NASDAQ:ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.